Stock ROVI LABORATORIOS FARMACEUTICOS ROVI, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Laboratorios Farmaceuticos Rovi, S.A.

Equities

ROVI

ES0157261019

Market Closed - BME
Other stock markets
 16:35:22 08/07/2024 BST 		5-day change 1st Jan Change
84.75 EUR +0.17% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. -2.36% +40.78%
06-26 Rovi receives non-binding offers for manufacturing business RE
05-08 Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ex-dividend day for final dividend
FA
Rovi receives non-binding offers for manufacturing business
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Rovi, Partners to Form Entity for Advanced Therapies R&D
MT
Rovi explores sale of unit that makes drugs for third parties
RE
The Ibex-35 opts for caution as corporate results continue to trickle in.
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
US FDA finds control lapses at Moderna manufacturing plant
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
CI
Ex-dividend day for final dividend
FA
Rovi denies being investigated for alleged public subsidies
RE
Laboratorios Farmaceuticos Rovi Denies Receiving Unlawful Public Grants
MT
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Laboratorios Farmaceuticos Rovi, S.A. Proposes Dividend for the Year 2022
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROVI Stock
  4. News Laboratorios Farmaceuticos Rovi, S.A.
  5. Highlights